Tactile Systems (TCMD) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue reached $73.2 million, up 7% year-over-year, with strong growth in lymphedema and airway clearance product lines.

• Net income improved to $4.3 million from a net loss of $0.1 million in Q2 2023.

• Adjusted EBITDA grew over 49% year-over-year, reflecting improved profitability and operating leverage.

• Leadership transition completed, with Sheri Dodd appointed President and CEO effective July 1, 2024.

• Received FDA 510(k) clearance for the Nimbl lymphedema therapy system, with limited launch planned for early fall 2024.

Financial highlights

• Lymphedema revenue rose 8% year-over-year to $64.7 million; airway clearance revenue increased 2% to $8.5 million.

• Gross margin improved to 73.9% from 70.7% last year; non-GAAP gross margin was 74.3%.

• Operating income increased to $5.8 million from $2.1 million in Q2 2023; non-GAAP operating income up to $6.5 million.

• Net income per diluted share was $0.18, compared to $0.00 in Q2 2023.

• Cash and cash equivalents stood at $73.6 million as of June 30, 2024.

Outlook and guidance

• 2024 revenue guidance revised to $293–$298 million (7–9% growth), down from $300–$305 million, due to Medicare documentation headwinds.

• Adjusted EBITDA guidance raised to $34–$36 million for 2024.

• Management expects cash, equivalents, and cash flows from operations to be sufficient for at least the next twelve months.

• Sequential quarterly growth expected to follow typical seasonality, with Q4 as the largest quarter.

• Inflation and changing prices are not expected to materially affect the business in the near term.